{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:25:06Z","timestamp":1793107506611,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Inflammatory bowel disease (IBD) is a debilitating condition driven by the dual pathologies of chronic inflammation and impaired intestinal barrier function. A significant clinical need exists for therapies that can effectively target both issues simultaneously. In this study, we investigated the therapeutic potential and mechanism of 5-hydroxy-\n                    <jats:italic>N,N,N<\/jats:italic>\n                    -trimethyltryptamine (5-OH-TMT), a quaternary ammonium salt derivative of bufotenine. We demonstrate that oral administration of 5-OH-TMT significantly ameliorates disease in two distinct murine models of experimental colitis (dextran sulfate sodium-induced and 2,4,6-trinitrobenzene sulfonic acid-induced colitis). The 5-OH-TMT treatment markedly improved clinical symptoms, potently suppressed pro-inflammatory cytokine production, and promoted a vital restoration of intestinal barrier integrity. Further exploration of the molecular basis of action of 5-OH-TMT using an unbiased proteomic screen revealed that 5-OH-TMT directly binds to and inhibits the mitochondrial serine protease high-temperature requirement A2 (HTRA2) protein. Additional mechanistic studies demonstrated that this inhibition of HTRA2 activates the Dectin-1\/CARD9 signaling pathway, a key axis in mucosal defense. Subsequent work confirmed that siRNA-mediated silencing of HTRA2 could phenocopy the drug\u2019s effects, including the suppression of pro-inflammatory NF-\u03baB phosphorylation. In conclusion, our findings establish that 5-OH-TMT mitigates colitis through a newly identified mechanism involving direct HTRA2 inhibition. This inhibition unleashes a protective Dectin-1-dependent program that both suppresses inflammation and restores barrier function. This work identifies the HTRA2-Dectin-1 axis as a promising new therapeutic target for IBD.\n                  <\/jats:p>","DOI":"10.1038\/s41401-026-01782-0","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:22:50Z","timestamp":1775100170000},"page":"2182-2195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["5-OH-TMT mitigates colitis through HTRA2 binding\u2013mediated activation of the Dectin-1 signaling pathway"],"prefix":"10.1038","volume":"47","author":[{"given":"Chun-xiu","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-ling","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-hang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-guo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-yue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"1782_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41577-024-01008-6","volume":"24","author":"MF Neurath","year":"2024","unstructured":"Neurath MF. Strategies for targeting cytokines in inflammatory bowel disease. Nat Rev Immunol. 2024;24:559\u201376.","journal-title":"Nat Rev Immunol"},{"key":"1782_CR2","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383:2652\u201364.","journal-title":"N Engl J Med"},{"key":"1782_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","volume":"14","author":"MF Neurath","year":"2014","unstructured":"Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329\u201342.","journal-title":"Nat Rev Immunol"},{"key":"1782_CR4","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","volume":"20","author":"MF Neurath","year":"2019","unstructured":"Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019;20:970\u20139.","journal-title":"Nat Immunol"},{"key":"1782_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41586-019-0992-y","volume":"567","author":"K Parikh","year":"2019","unstructured":"Parikh K, Antanaviciute A, Fawkner-Corbett D, Jagielowicz M, Aulicino A, Lagerholm C, et al. Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature. 2019;567:49\u201355.","journal-title":"Nature"},{"key":"1782_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1126\/science.aan0814","volume":"359","author":"V Mohanan","year":"2018","unstructured":"Mohanan V, Nakata T, Desch AN, L\u00e9vesque C, Boroughs A, Guzman G, et al. C1orf106 is a colitis risk gene that regulates stability of epithelial adherens junctions. Science. 2018;359:1161\u20136.","journal-title":"Science"},{"key":"1782_CR7","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.stem.2022.08.008","volume":"29","author":"L Chen","year":"2022","unstructured":"Chen L, Jiao T, Liu W, Luo Y, Wang J, Guo X, et al. Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal. Cell Stem Cell. 2022;29:1366\u20131381.e9.","journal-title":"Cell Stem Cell"},{"key":"1782_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev-immunol-032414-112151","volume":"34","author":"JM Peloquin","year":"2016","unstructured":"Peloquin JM, Goel G, Villablanca EJ, Xavier RJ. Mechanisms of pediatric inflammatory bowel disease. Annu Rev Immunol. 2016;34:31\u201364.","journal-title":"Annu Rev Immunol"},{"key":"1782_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn8699","volume":"17","author":"L-L Bao","year":"2025","unstructured":"Bao LL, Yu YQ, Gonz\u00e1lez-Acera M, Patankar JV, Giessl A, Sturm G, et al. Epithelial OPA1 links mitochondrial fusion to inflammatory bowel disease. Sci Transl Med. 2025;17:eadn8699.","journal-title":"Sci Transl Med"},{"key":"1782_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","volume":"12","author":"S Singh","year":"2018","unstructured":"Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis. 2018;12:635\u201343.","journal-title":"J Crohns Colitis"},{"key":"1782_CR11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/ecco-jcc\/jjz162","volume":"14","author":"MP Sparrow","year":"2020","unstructured":"Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, et al. Therapeutic drug monitoring of biologics during induction to prevent primary non-response. J Crohns Colitis. 2020;14:542\u201356.","journal-title":"J Crohns Colitis"},{"key":"1782_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","volume":"53","author":"B Verstockt","year":"2018","unstructured":"Verstockt B, Ferrante M, Vermeire S, Van Assche G. New treatment options for inflammatory bowel diseases. J Gastroenterol. 2018;53:585\u201390.","journal-title":"J Gastroenterol"},{"key":"1782_CR13","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.3748\/wjg.v29.i29.4481","volume":"29","author":"L-F Wang","year":"2023","unstructured":"Wang LF, Chen PR, He SK, Duan SH, Zhang Y. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review. World J Gastroenterol. 2023;29:4481\u201398.","journal-title":"World J Gastroenterol."},{"key":"1782_CR14","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399:2200\u201311.","journal-title":"Lancet"},{"key":"1782_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48997-5","volume":"15","author":"EE Aspholm","year":"2024","unstructured":"Aspholm EE, Lidman J, Burmann BM. Structural basis of substrate recognition and allosteric activation of the proapoptotic mitochondrial HtrA2 protease. Nat Commun. 2024;15:4592.","journal-title":"Nat Commun"},{"key":"1782_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.4161\/auto.22920","volume":"9","author":"S Kang","year":"2013","unstructured":"Kang S, Fernandes-Alnemri T, Alnemri ES. A novel role for the mitochondrial HTRA2\/OMI protease in aging. Autophagy. 2013;9:420\u20131.","journal-title":"Autophagy"},{"key":"1782_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ncb1644","volume":"9","author":"H Plun-Favreau","year":"2007","unstructured":"Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, et al. The mitochondrial protease HtrA2 is regulated by Parkinson\u2019s disease-associated kinase PINK1. Nat Cell Biol. 2007;9:1243\u201352.","journal-title":"Nat Cell Biol"},{"key":"1782_CR18","doi-asserted-by":"publisher","first-page":"7273","DOI":"10.2147\/IJN.S469742","volume":"19","author":"D Zhang","year":"2024","unstructured":"Zhang D, Zhai B, Sun J, Cheng J, Zhang X, Guo D. Advances on delivery system of active ingredients of dried toad skin and toad venom. Int J Nanomed. 2024;19:7273\u2013305.","journal-title":"Int J Nanomed"},{"key":"1782_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113677","volume":"269","author":"D Xu","year":"2021","unstructured":"Xu D, Wang J, Chen W, Yang X, Zhou J, Ma H, et al. Evaluation of analgesic and anti-inflammatory actions of indolealkylamines from toad venom in mice using lipidomics and molecular docking. J Ethnopharmacol. 2021;269:113677.","journal-title":"J Ethnopharmacol"},{"key":"1782_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113492","volume":"153","author":"L Shen","year":"2022","unstructured":"Shen L, Lv X, Yang X, Deng S, Liu L, Zhou J, et al. Bufotenines-loaded liposome exerts anti-inflammatory, analgesic effects and reduce gastrointestinal toxicity through altering lipid and bufotenines metabolism. Biomed Pharmacother. 2022;153:113492.","journal-title":"Biomed Pharmacother"},{"key":"1782_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111749","volume":"140","author":"J Wang","year":"2021","unstructured":"Wang J, Xu D, Shen L, Zhou J, Lv X, Ma H, et al. Anti-inflammatory and analgesic actions of bufotenine through inhibiting lipid metabolism pathway. Biomed Pharmacother. 2021;140:111749.","journal-title":"Biomed Pharmacother"},{"key":"1782_CR22","first-page":"454","volume":"19","author":"C Zhao","year":"2021","unstructured":"Zhao C, Chen M, Sun SL, Wang JJ, Zhong Y, Chen HH, et al. Bufotenine and its derivatives: synthesis, analgesic effects identification and computational target prediction. Chin J Nat Med. 2021;19:454\u201363.","journal-title":"Chin J Nat Med."},{"key":"1782_CR23","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1016\/j.apsb.2024.03.017","volume":"14","author":"J Hu","year":"2024","unstructured":"Hu J, Liu W, Zou Y, Jiao C, Zhu J, Xu Q, et al. Allosterically activating SHP2 by oleanolic acid inhibits STAT3-Th17 axis for ameliorating colitis. Acta Pharm Sin B. 2024;14:2598\u2013612.","journal-title":"Acta Pharm Sin B"},{"key":"1782_CR24","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1038\/s41589-023-01355-w","volume":"19","author":"Y Tian","year":"2023","unstructured":"Tian Y, Wan N, Zhang H, Shao C, Ding M, Bao Q, et al. Chemoproteomic mapping of the glycolytic targetome in cancer cells. Nat Chem Biol. 2023;19:1480\u201391.","journal-title":"Nat Chem Biol"},{"key":"1782_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.apsb.2024.12.041","volume":"15","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Zhao L, Yan W, Ma H, Zhao W, Qu J, et al. Celastrol directly targets LRP1 to inhibit fibroblast-macrophage crosstalk and ameliorates psoriasis progression. Acta Pharm Sin B. 2025;15:876\u201391.","journal-title":"Acta Pharm Sin B"},{"key":"1782_CR26","doi-asserted-by":"publisher","first-page":"21984","DOI":"10.1073\/pnas.0910040106","volume":"106","author":"B Lomenick","year":"2009","unstructured":"Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, et al. Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci USA. 2009;106:21984\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1782_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49049-8","volume":"15","author":"E-K Choi","year":"2024","unstructured":"Choi EK, Rajendiran TM, Soni T, Park JH, Aring L, Muraleedharan CK, et al. The manganese transporter SLC39A8 links alkaline ceramidase 1 to inflammatory bowel disease. Nat Commun. 2024;15:4775.","journal-title":"Nat Commun"},{"key":"1782_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33844-2","volume":"13","author":"A Fazio","year":"2022","unstructured":"Fazio A, Bordoni D, Kuiper JWP, Weber-Stiehl S, Stengel ST, Arnold P, et al. DNA methyltransferase 3A controls intestinal epithelial barrier function and regeneration in the colon. Nat Commun. 2022;13:6266.","journal-title":"Nat Commun"},{"key":"1782_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature06005","volume":"448","author":"RJ Xavier","year":"2007","unstructured":"Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427\u201334.","journal-title":"Nature"},{"key":"1782_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1146\/annurev-immunol-042617-053055","volume":"36","author":"HH Uhlig","year":"2018","unstructured":"Uhlig HH, Powrie F. Translating immunology into therapeutic concepts for inflammatory bowel disease. Annu Rev Immunol. 2018;36:755\u201381.","journal-title":"Annu Rev Immunol"},{"key":"1782_CR31","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1056\/NEJMoa0901053","volume":"361","author":"B Ferwerda","year":"2009","unstructured":"Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009;361:1760\u20137.","journal-title":"N Engl J Med"},{"key":"1782_CR32","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature04926","volume":"442","author":"O Gross","year":"2006","unstructured":"Gross O, Gewies A, Finger K, Sch\u00e4fer M, Sparwasser T, Peschel C, et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature. 2006;442:651\u20136.","journal-title":"Nature"},{"key":"1782_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ni1408","volume":"8","author":"PR Taylor","year":"2007","unstructured":"Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, Findon H, et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol. 2007;8:31\u20138.","journal-title":"Nat Immunol"},{"key":"1782_CR34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature10071","volume":"472","author":"HS Goodridge","year":"2011","unstructured":"Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, et al. Activation of the innate immune receptor Dectin-1 upon formation of a \u201cphagocytic synapse. Nature. 2011;472:471\u20135.","journal-title":"Nature"},{"key":"1782_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41590-023-01447-8","volume":"24","author":"X Zhu","year":"2023","unstructured":"Zhu X, Sakamoto S, Ishii C, Smith MD, Ito K, Obayashi M, et al. Dectin-1 signaling on colonic \u03b3\u03b4 T cells promotes psychosocial stress responses. Nat Immunol. 2023;24:625\u201336.","journal-title":"Nat Immunol"},{"key":"1782_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/bs.apha.2024.10.002","volume":"101","author":"Y Li","year":"2024","unstructured":"Li Y, Huang M, Cardinale S, Su Y, Peters DE, Slusher BS, et al. Dectin-1 as a therapeutic target for inflammatory bowel disease. Adv Pharmacol. 2024;101:237\u201364.","journal-title":"Adv Pharmacol"},{"key":"1782_CR37","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.4049\/jimmunol.2001337","volume":"206","author":"W Han","year":"2021","unstructured":"Han W, Tang C, Baba S, Hamada T, Shimazu T, Iwakura Y. Ovalbumin-induced airway inflammation is ameliorated in Dectin-1-deficient mice, in which pulmonary regulatory T cells are expanded through modification of intestinal commensal bacteria. J Immunol. 2021;206:1991\u20132000.","journal-title":"J Immunol"},{"key":"1782_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.chom.2015.07.003","volume":"18","author":"C Tang","year":"2015","unstructured":"Tang C, Kamiya T, Liu Y, Kadoki M, Kakuta S, Oshima K, et al. Inhibition of Dectin-1 signaling ameliorates colitis by inducing lactobacillus-mediated regulatory T cell expansion in the intestine. Cell Host Microbe. 2015;18:183\u201397.","journal-title":"Cell Host Microbe."},{"key":"1782_CR39","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1126\/science.1221789","volume":"336","author":"ID Iliev","year":"2012","unstructured":"Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science. 2012;336:1314\u20137.","journal-title":"Science"},{"key":"1782_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8162","volume":"10","author":"T Takagawa","year":"2018","unstructured":"Takagawa T, Kitani A, Fuss I, Levine B, Brant SR, Peter I, et al. An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis. Sci Transl Med. 2018;10:eaan8162.","journal-title":"Sci Transl Med"},{"key":"1782_CR41","doi-asserted-by":"publisher","first-page":"9774","DOI":"10.1111\/jcmm.15559","volume":"24","author":"J Wang","year":"2020","unstructured":"Wang J, Tian J, He YH, Yang ZW, Wang L, Lai YX, et al. Role of CARD9 in inflammatory signal pathway of peritoneal macrophages in severe acute pancreatitis. J Cell Mol Med. 2020;24:9774\u201385.","journal-title":"J Cell Mol Med."},{"key":"1782_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1580-7","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang C, He A, Liu S, He Q, Luo Y, He Z, et al. Inhibition of HtrA2 alleviated dextran sulfate sodium (DSS)-induced colitis by preventing necroptosis of intestinal epithelial cells. Cell Death Dis. 2019;10:344.","journal-title":"Cell Death Dis"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01782-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01782-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01782-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:41:31Z","timestamp":1784623291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01782-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1782"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01782-0","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}